Stock Traders Purchase Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 19,634 call options on the company. This represents an increase of 325% compared to the average daily volume of 4,623 call options.

Analyst Upgrades and Downgrades

Separately, Maxim Group boosted their price objective on shares of SELLAS Life Sciences Group from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, July 16th.

Insider Transactions at SELLAS Life Sciences Group

In related news, Director Jane Wasman bought 20,000 shares of the stock in a transaction that occurred on Friday, May 30th. The stock was purchased at an average cost of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the director owned 30,400 shares in the company, valued at $51,376. This trade represents a 192.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently modified their holdings of the business. Blair William & Co. IL acquired a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter worth about $35,000. Virtu Financial LLC boosted its position in shares of SELLAS Life Sciences Group by 30.9% during the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company’s stock valued at $58,000 after purchasing an additional 12,706 shares in the last quarter. Northern Trust Corp boosted its position in shares of SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company’s stock valued at $140,000 after purchasing an additional 33,878 shares in the last quarter. Brooklyn FI LLC bought a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at about $677,000. Finally, Geode Capital Management LLC boosted its holdings in shares of SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company’s stock worth $763,000 after buying an additional 128,355 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Trading Down 5.1%

NASDAQ SLS opened at $1.69 on Wednesday. The stock has a market cap of $168.63 million, a P/E ratio of -4.45 and a beta of 2.31. The company’s fifty day simple moving average is $1.80 and its 200-day simple moving average is $1.46. SELLAS Life Sciences Group has a 52 week low of $0.77 and a 52 week high of $2.27.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. On average, research analysts expect that SELLAS Life Sciences Group will post -0.57 EPS for the current fiscal year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.